Methods: Echocardiographic parameters of cardiac and vascular stiffness (EaI, Ees and Eed)
were quantified in 28 patients with OSA (mean [SD] age 51 [11] years, 79% male) and 28 treated subjects with HHT (mean [SD] age 48 [12] years, 61% male). Twenty three OSA patients were treated with CPAP for median of 26 weeks. Ea was calculated from stroke volume and systolic BP and adjusted by body area (EaI). Both study groups had preserved and comparable left ventricle (LV) contractility.
Results: There was no significant differences in arterial elastance index (EaI, p=0.94), endsystolic elastance (Ees, p=0.5), end-diastolic elastance (Eed, p=0.63) and arterial-ventricular interaction (Ees/Ea, p=0.62) between OSA and HHT groups. After CPAP therapy, there was a significant reduction in arterial elastance index (EaI; paired t-test, p=0.013), and arterialventricular interaction (Ees/Ea; paired t-test, p=0.004). End-systolic elastance (Ees, p=0.17), end-diastolic elastance (Eed, p=0.66) parameters did not change significantly.
Conclusions: OSA patients and HHT patients have similar parameters of elastance and ventricular-arterial coupling. CPAP treatment in OSA patients significantly improved ventricular-arterial coupling.
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Introduction
Obstructive sleep apnoea (OSA) is a pathological condition associated with recurrent hypoxia, disturbed sleep, and ultimately excessive negative intrathoracic pressure that leads to detrimental effects on cardiovascular system and an increased cardiovascular morbidity. [1, 2] Mechanisms of OSA-related cardiac and arterial damage are diverse and still insufficiently understood. Hypertension is common in OSA and predisposes to cardiac diastolic dysfunction, arterial stiffening as well as endothelial dysfunction. [3] [4] [5] [6] The pathogenic mechanisms of OSA also involve increase sympathetic activity, inflammation and oxidative stress, and might thus disturb cardiovascular performance even in patients without overt hypertension.
Impairment of cardiac and vascular elastic properties is recognised as a critical element of cardiovascular pathophysiology. [7, 8] is well documented enhanced arterial stiffness in OSA, it is plausible that ventricular-arterial coupling can also be impaired in OSA, but this has not been previously investigated. [12] Continuous positive airway pressure (CPAP) treatment of mild to moderate OSA has been shown to improve symptoms, quality of life and outcomes, and has been accepted as the 'gold standard' treatment in OSA [13] . The effects of CPAP on cardiovascular function in hypertension free OSA patients without pre-existing cardiovascular disease has not been established. [14, 15] The data on effect of CPAP on cardiac function are controversial, although scarce data are available on the effect of CPAP treatment on the parameters of arterial and cardiac elastance. [16] [17] [18] In this study, we tested the hypothesis that abnormal arterial [arterial elastance (Ea); arterial elastance index (EaI)] and ventricular [End-systolic elastance (Ees) and End-diastolic elastance (Eed)] elastances are present in untreated OSA patients, compared to treated 'highrisk' hypertension (HHT) patients, and second, that these parameters in OSA can be improved after CPAP therapy.
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Methods
In this prospective study twenty eight consecutive subjects with a confirmed diagnosis of moderate-severe OSA have been compared with 28 treated 'high risk hypertensives' (HHT).
OSA group included subjects with aponea-hypopnoea index (AHI)>15, established by multichannel polysomnography (FSI Grey Flash recorder, Stowood Scientific Instruments Ltd, Oxford UK) and recruited from the Sleep laboratory in City Hospital, Birmingham, UK.
HHT was defined by the presence of established hypertension associated with one or more of the following cardiovascular risk factors: LV hypertrophy (Sokolow-Lyon or Cornell voltage criteria), age >55 years, peripheral vascular disease, or known family history of CAD, a definition used in contemporary clinical trials [19] . Exclusion criteria were: secondary hypertension related to renal, renovascular or endocrine causes, CAD, valvular heart disease, LV ejection fraction <50%, diabetes mellitus, liver disease, serum creatinine >200 µmol/L, malignancy, recent (<3 months) arterial or venous thromboembolic disease, active infections and/or a history of inflammatory or connective tissue disorders.
Participants were asked to abstain from alcohol, tea, coffee and smoking for 24 hours prior to the study. Participants were asked not to take their medications on the study day. All scans were done in a darkened, quiet, temperature controlled room after rest for 15-20 minutes.
After baseline scan, patients with OSA were provided with an automated CPAP device Measurements of arterial-vascular interaction were made as reported and validated previously. [20] [21] [22] Effective arterial elastance index (EaI) was calculated as an effective arterial elastance (Ea, based on 3DE stroke volume and systolic BP) adjusted by body area.
End-systolic elastance (Ees) was calculated using systolic and diastolic BP, stroke volume, pre-ejection and total systolic times. End-dystolic elastance (Eed) was established from the ratio of mitral inflow early diastolic filling velocity and the mitral annular early diastolic TDI velocity (E') divided by volume filling during diastole. In the absence of significant aortic regurgitation, stroke volume can be used as an indicator of ventricular filling volume. The Ea/Ees ratio was used as a measure of arterial-ventricular interaction. The inter-and intraobserver variability for echocardiography parameters was 11% and 6.8%, respectively.
Power calculation
On the basis on our previous work on parameters of elastance, we calculated that a sample size of at least 15 patients in each group would have an 80% power to detect a significant difference ≥0.5 standard deviation in effective arterial elastance. [22] Statistical methods 
Data are presented as mean [standard deviations, SD] for normally distributed data; or median [inter-quartile range, IQR] for non-normally distributed data. Comparisons between
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Results
Groups of patients with OSA and HHT were well matched for age, sex, body mass index, cardiovascular risk factors and LV ejection fraction (Table 1) 
Vascular-ventricular interactions
There were no significant differences in arterial elastance index (EaI, p=0.94), end-systolic elastance (Ees, p=0.50), end-diastolic elastance (Eed, p=0.63) and arterial-ventricular interaction (Ea/Ees, p=0.62) between OSA and HHT groups (Table 1 ). In the OSA group, Eed was positively correlated with age (r=0.40, p=0.037) and Ees was positively correlated with heart rate (r=0.42; p=0.026)
Effect of CPAP therapy in obstructive sleep apnoea patients
Systolic blood pressure was significantly reduced after CPAP therapy (p<0.001), and there was a significant improvement in LVEF on 2DE (p=0.02) ( Table 2) .
CPAP therapy resulted in significant reduction in arterial elastance index (EaI, p=0.013), and arterial-ventricular interaction (Ees/Ea, p=0.004) (Figure 1 ). End-systolic elastance (Ees, p=0.17), end-diastolic elastance (Eed, p=0.66) parameters did not change significantly.
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Discussion
In this study, we show for the first time that arterial elastance and arterial-ventricular interactions in patients with OSA are significantly improved by CPAP therapy. We found that OSA patients and HHT patients had similar parameters of elastance and ventricular-arterial coupling. The non-invasive nature of our approach makes it applicable for clinical use and particularly for monitoring of treatment effects, for example, with CPAP therapy. Indeed, parameters of elastance used in the study provide an advance in the assessment of the cardiovascular elastic properties and the echocardiographic method has been validated by direct comparisons with invasive analysis of pressure-volume curves. [20, 21] Of interest, the study has not found any difference in parameters of elastance and vascularcardiac interactions between normotensive subjects with OSA and patients with HHT. This indicates presence of abnormal ventricular-arterial coupling in OSA irrespectively of hypertensive status that is common in this condition.
Arterial elastance characterises the artery's capacity to expand and contract in synchrony with cardiac cycle. Cardiac elastance reflects increased myocardial mass, a shift in the myocardiac content characterised by reduced myocyte number and enhanced collagen deposition and cross-linking. [23] Impaired cardiac elastance is likely to contribute to cardiac overload and diastolic dysfunction common in OSA, whilst high Ees may result in increased myocardial oxygen consumption, and disturb myocardial perfusion reserve. [24] Appropriate coupling of heart to artery (e.g., estimated by the Ea/Ees ratio) is essential for effective transfer of blood from heart to the peripheral circulation without excessive changes in blood pressure and it is a significant factor of overall cardiovascular performance.. [25, 26] 
Limitations
The study groups are relatively small and larger studies are essential to established outcomerelated impact on the observed changes in elastance after CPAP therapy. Also, the study does not provide a complete mechanistic explanation of the findings, which would also need to be done in appropriately designed studies. M A N U S C R I P T
Conclusions
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